APC	antigen-presenting cells	IRE	irreversible electroporation
BCC	basal cell carcinoma	LAPC	locally advanced pancreatic cancer
BCG	bacillus of Calmette-Guerin	MA-IRE	margin accentuation IRE
BEST	bleomycin electrosclerotherapy	MID	minimal important difference
BRPC	borderline resectable pancreatic cancer	mpMRI	multiparametric MRI
Ca-EP	calcium electroporation	MRI	magnetic resonance imaging
CEUS	contrast-enhanced ultrasound	MWA	microwave ablation
CR	complete response	NK	natural killer
CRLM	colorectal liver metastases	NSCLC	non-small cell lung cancer
CRR	complete response rate	ORR	overall response rate
cSCC	cutaneous squamous cell carcinoma	OS	overall survival
csPCa	clinically significant prostate cancer	PDAC	pancreatic ductal adenocarcinoma
CT	computed tomography	PEF	pulsed electric field
DAMPS	damage-associated molecular patterns	PET-CT	positron emission tomography-CT
DFS	disease-free survival	PFS	progression-free survival
ECT	electrochemotherapy	PMCA	plasma membrane calcium ATPase
EP	electroporation	PSA	prostatic specific antigen
ESOPE	European standard operating procedures of ECT	PSMA	prostate-specific membrane antigen
FG-ECT	fixed geometry ECT	QoL	quality of life
FIRE	focal IRE	RECIST	response evaluation criteria in solid tumours
GBM	glioblastoma	RESPECT	registry on percutaneous ECT
GET	gene electrotransfer	RFA	radiofrequency ablation
HCC	hepatocellular carcinoma	STING	stimulator of interferon gamma
H-FIRE	high-frequency IRE	TRAIL	tumour necrosis factor-related apoptosis-inducing ligand
HNSCC	head and neck squamous cell carcinoma	TTF	tumour-treating field
ICC	intrahepatic cholangiocarcinoma	US	ultrasound
ICD	immunogenic cell death	VG-ECT	variable geometry ECT
ILI	isolated limb infusion	V-SCC	vulvar squamous cell carcinoma
ILP	isolated limb perfusion	WCE	world congress of electroporation
InspECT	International network for sharing practices of ECT